The article discusses the stigma surrounding cannabis and the importance of destigmatizing it, especially for those who rely on it for medical purposes. The author argues that cannabis should be as socially acceptable as alcohol and emphasizes the need for education on the plant's safety and benefits. Advocacy for cannabis is encouraged, including wearing cannabis-themed apparel and being vocal about its positive aspects. However, the author also acknowledges the potential for abuse and the existence of negative aspects, such as the availability of harmful, illegally produced cannabis. The article calls for a balanced view of cannabis, advocating for its acceptance and legalization while recognizing the need for education and harm reduction.

The article criticizes the stigma surrounding THC, the psychoactive compound in cannabis, contrasting it with the more accepted CBD products. It highlights the medicinal benefits of THC, citing scientific evidence and the World Health Organisation's statements on its low toxicity. The author, Ruby Deevoy, argues that the negative perception of THC is based on misinformation and fear-mongering, and that THC can be safer than alcohol and prescription drugs. The article calls for a reevaluation of drug laws and suggests that regulated, accurately labeled THC products could be used safely and beneficially. It also mentions the work of Kent Scientific Services in testing CBD products and finding many contained illegal levels of THC, which sparked controversy.

The article discusses the historical and contemporary use of cannabis, particularly CBD, in enhancing sexual experiences. It highlights the lack of scientific research in the area but points to anecdotal evidence and limited studies that suggest benefits such as reduced performance anxiety, increased libido, and enhanced pleasure. The article explains how cannabis can alleviate pain during sex, increase blood flow, and potentially improve orgasm intensity. It also touches on the use of cannabis in the LGBTQ+ community, suggesting it can help reduce anxiety and shame associated with sexual activity. The potential of CBD as a natural aphrodisiac and its role in maintaining higher levels of endocannabinoids in the body is also discussed. Additionally, the article mentions the use of CBD-infused products like lubricants to relieve vaginal pain and dryness, and enhance pleasure during sex.

The article discusses the lack of awareness and education regarding the endocannabinoid system (ECS), a major physiological system, among the general public and medical professionals. Despite the ECS's crucial role in health and its interaction with cannabis, only 13% of US medical schools include it in their curriculum. The article highlights the existence of over 41,000 studies on the ECS and cannabis, contradicting the government's claim of insufficient evidence for medical cannabis. It also reveals that endocannabinoid receptors are present in mitochondrial cell walls, emphasizing the importance of a functioning ECS. Additionally, the article notes that other plants besides cannabis can support the ECS and suggests that endocannabinoid deficiency may underlie several 'incurable' conditions, pointing to potential treatment options with cannabinoid therapy. The article encourages self-education and advocates for improved medical training and access to cannabis for therapeutic use.

The article discusses the common issues users face when trying CBD, suggesting that improper use or incorrect product selection may be the cause of unsatisfactory results. It emphasizes the importance of consistency in CBD use, recommending daily intake and microdosing for at least six weeks. The article provides tips to enhance CBD absorption, such as taking it sublingually after eating or brushing teeth, and ensuring a diet rich in healthy fats. It advises on choosing the right CBD product based on individual needs and highlights the potential benefits of full-spectrum CBD. The article also touches on the role of terpenes in enhancing the therapeutic effects of CBD and suggests that those with complex health issues consider getting a medical cannabis prescription. No specific brands or organizations are mentioned, and the article seems to focus on general advice rather than promoting particular products or services.

The article discusses the complexities of cannabis use, acknowledging both its potential for abuse and its benefits for medicinal, spiritual, and recreational purposes. The author argues against the assumption that cannabis advocates are unaware of the risks associated with cannabis use. Dr. Ben Sessa, Chief Medical Officer at AWAKN Life Science Inc, is quoted discussing the multifaceted nature of mental health issues and addictions. The article highlights the dangers of contaminated cannabis in the illegal market and advocates for legalization to ensure quality control and safe usage. It compares the societal acceptance of substances like sugar and alcohol, despite their health risks, to the stigmatization of cannabis. The author concludes that while drug abuse cannot be completely eradicated, legalization and education can help reduce harm and support those struggling with addiction.

The article discusses the safety concerns surrounding over-the-counter medicines like Calpol, highlighting its potential side effects such as liver damage and hyperactivity in children. It contrasts this with the safety profile of medical cannabis, which, despite being treated with caution and skepticism, has been shown to have a low incidence of serious side effects and no recorded deaths. The article criticizes the reliance on Randomised Control Trials for evidence of safety and advocates for the consideration of real-world evidence (RWE). It mentions the UN's reclassification of cannabis and criticizes the UK's National Institute for Health and Care Excellence (NICE) for not considering RWE. The article also touches on the negative consequences of cannabis prohibition in the UK, such as unsafe self-medication, unregulated products, lack of education, and legal repercussions.

The article discusses the differences in effects between smoking cannabis and consuming cannabis edibles, such as brownies. It explains that edibles can produce a stronger high due to the presence of THC and its conversion to 11-hydroxy-THC when digested. The article highlights the importance of consuming edibles slowly due to their unpredictable potency and individual metabolism rates. It also touches on the medicinal benefits of various types of THC, including THCA, THCV, Delta-8 THC, and Delta-9 THC. The piece emphasizes that while edibles take longer to take effect, they can offer more effective and longer-lasting results due to the way cannabinoids are processed in the body. The article advises caution when trying edibles for the first time, suggesting that users start with small amounts to avoid overwhelming experiences.

A study by Drug Science has found that whole plant cannabis oil significantly reduces seizure frequency in children with severe, treatment-resistant epilepsy, with an 86% reduction observed. The study highlights the potential of cannabis oil, which includes THC, to outperform other epilepsy drugs and even lead to some patients becoming seizure-free. Despite the evidence and the UK's status as a major medical cannabis exporter, NHS prescriptions for whole plant cannabis are rare, with only three issued since a 2018 law change. The cost of private prescriptions is prohibitively expensive for many families. The article discusses barriers to wider NHS access, including pharmaceutical industry resistance, educational gaps in medical training, and regulatory challenges. It also touches on the broader implications for the healthcare system and the potential benefits of medical cannabis for various conditions.

The article discusses the widespread issue of sleep deprivation and chronic insomnia in the UK, highlighting that a significant portion of the population does not get the recommended 8 hours of sleep per night. It explores the potential of CBD (Cannabidiol) as a natural remedy for sleep problems, focusing on its interaction with serotonin receptors and the endocannabinoid system. The article suggests that CBD may help regulate serotonin levels, which in turn can aid in the production of melatonin, a hormone that regulates sleep. It also addresses the relationship between stress and sleep, noting that CBD may help manage stress by supporting the body's endocannabinoid system. The piece advocates for the use of CBD oil, and possibly CBDA, as a daily supplement to potentially improve sleep quality.

The article by Ruby Deevoy discusses the concerning rise in screen time, with statistics indicating that adults spend a significant portion of their lives staring at screens. It highlights the addictive nature of social media platforms like Instagram, Facebook, Twitter, and TikTok, and the lawsuit filed against Meta for its platforms causing compulsive use in children. The article delves into the negative effects of excessive screen time, including desensitization of the brain's reward system, an increase in mental health conditions, the physical strain known as 'Tech Neck', and potential radiation exposure from devices like the iPhone 12, which was banned in France. The piece concludes by advocating for a digital detox as a wellness trend, suggesting the use of Eresos CBD oil to aid in the process of disconnecting from digital devices.

The article discusses the innovative treatments for alcoholism offered by Awakn, a clinic in London that combines psychiatric help with psychedelic drugs like Ketamine. In England, a large number of dependent drinkers do not receive effective treatment, with many relapsing within 6 months. Awakn's approach, which includes Ketamine infusions and therapy sessions, aims to disrupt depressive and addictive thought processes and encourage neuroplasticity. Trials have shown promising results, with significantly higher abstinence rates compared to other treatments. The article also touches on the potential of Psilocybin for treating depression, though its legal status in the UK is a barrier. Ketamine therapy at Awakn is available for various disorders but is not NHS-funded and has eligibility criteria.

In the agony aunt column 'Ask Ruby', Ruby Deevoy, a CBD and cannabis expert, responds to a reader's query about managing chronic pain from a pelvic injury while awaiting surgery delayed by the Covid-19 pandemic. Ruby expresses sympathy and discusses the limitations of opioids, which are no longer recommended by NICE for chronic pain. She suggests medical cannabis as a legal and potentially effective alternative in the UK, cautioning against street drugs due to quality and safety concerns. Ruby recommends consulting with cannabis clinics in the UK and mentions Leva, an online clinic for persistent pain, and the Twenty21 project, which offers reduced-cost medical cannabis treatments. She emphasizes the importance of care and proper medical guidance in using cannabis for pain relief.

Ruby Deevoy, a CBD and cannabis expert, addresses a reader's question about interpreting lab reports for CBD products in her column Ask Ruby. She emphasizes the importance of checking third-party lab reports, or Certificates of Analysis (COA), to ensure the product is free from contaminants like heavy metals and pesticides, and to verify that it contains the advertised cannabinoids. Ruby explains that lab reports can vary but generally include tables listing cannabinoids, contaminants, and sometimes terpenes. She clarifies terms such as LOQ (Limit of Quantitation), and how to understand the percentages and measurements indicated in the report. Ruby also points out that labels like 'organic', 'broad spectrum', and 'full spectrum' may not always be accurate, and that a true full-spectrum oil should contain several cannabinoids in significant amounts alongside CBD.

The article discusses the stigma surrounding cannabis use, particularly in the context of its medical applications. Despite the legalisation in various countries and states, and the UN's recognition of cannabis's therapeutic value, societal perceptions are still influenced by nearly a century of prohibition and negative stereotypes. The piece highlights the benefits of medical cannabis for conditions like epilepsy, chronic pain, depression, and PTSD, and shares personal stories of two mothers, Dr. Callie Seaman and Gillian Flood, who use cannabis to manage their medical conditions and assert that it makes them better parents. The article calls for a change in the public's understanding of cannabis users, who range from mothers to athletes and billionaires, and emphasizes the need to overcome outdated prejudices.

The article is a first-person account of the author's experience at the Beckley Retreat, a premier magic mushroom retreat located in the Venwoude estate, Netherlands. Co-founded by Amanda Feilding and Neil Markey, the retreat combines scientific understanding with shamanism and indigenous wisdom. The author describes the preparation, the psychedelic experiences, and the integration process that follows the retreat. The retreat includes yoga, meditation, breath work, and group sharing sessions. The author reflects on the profound personal insights and the sense of interconnectedness felt during the retreat. The experience is likened to intensive therapy, with lasting impact on the author's perspective on life and self-awareness.

Ruby Deevoy, a CBD and cannabis expert, responds to a reader's inquiry about the differences between smoking or vaping cannabis flower and hash. She explains that hash is a concentrated form of cannabis made from the resin of the plant and can be more potent than weed, with THC levels potentially reaching up to 60%. However, the actual THC content can vary widely, as demonstrated by a study showing hash from Lebanon, India, and Morocco with only up to 16% THC. High-quality hash may also contain higher levels of CBD and a unique terpene called hashinene, which could offer additional therapeutic benefits. The effects of hash can vary depending on how it's made and the strain of cannabis used, with some people finding it to produce a mellow high with less anxiety. Deevoy concludes that the choice between weed and hash is a personal preference and encourages trying both to see which suits one's needs best.

The article discusses the challenges faced by patients in the UK in accessing whole plant cannabis for medical treatment, despite its legalization for prescription in 2018. It highlights the bureaucratic hurdles within the NHS, where GPs cannot prescribe cannabis and must refer patients to consultants who are influenced by pharmaceutical companies. The article criticizes the NHS for only prescribing three patients with whole plant cannabis and favoring less effective isolate medications like Epidyolex, which has generated significant revenue for GW Pharmaceuticals. The author argues that there is ample evidence of cannabis's safety and efficacy, citing the Drug Science program, Project Twenty21. The article suggests that financial interests are preventing wider access to cannabis, which could benefit over a million people with serious conditions in the UK.

The article discusses the importance of understanding menopause and the various symptoms and health issues it can bring. It highlights the lack of research and education on women's health, particularly menopause. The author suggests that with the right supplements, diet, and emotional support, the challenges of menopause can be eased. Traditional remedies like Black Cohosh and Ashwagandha are mentioned, as well as the use of cannabis and CBD oil for their potential benefits in treating menopausal symptoms. The article explains how CBD oil can boost serotonin levels, which may help with insomnia, depression, anxiety, and libido. It also touches on the role of the endocannabinoid system in female reproductive events and the potential of CBD and CBDa to alleviate menopausal symptoms by interacting with estrogen receptors and reducing inflammation. The piece concludes by emphasizing the need for more research on cannabis's role in menopause treatment, while suggesting that anecdotal evidence supports the use of high-quality, full-spectrum CBD oil for symptom relief.

Ruby Deevoy, a health, science, and wellbeing journalist, discusses the importance of self-care and mental health, particularly after the holiday season. She encourages readers to write a love letter to themselves as a form of self-appreciation and to recognize their own worth. Deevoy also suggests looking for 'glimmers' or moments of joy and security to improve mental health. Additionally, she emphasizes the importance of setting boundaries for maintaining healthy relationships and personal well-being. The article provides advice on how to identify and enforce personal boundaries and reminds readers to be patient with themselves as they make these changes. Deevoy concludes by highlighting that while self-care practices like using face masks and CBD drops are beneficial, they should complement deeper self-work for a transformative new year.

The article discusses the stigma surrounding cannabis use for medical purposes in the UK, despite its availability on prescription. The author acknowledges the challenges individuals face when considering using cannabis as medicine, particularly due to the negative perceptions held by family and friends. The article provides advice on how to approach conversations about cannabis use with loved ones, emphasizing the importance of being in a calm state, choosing the right timing, and being prepared for various reactions. The author suggests seeking support from wellbeing coach Vikki Rimmer and Medcan Support, which offers educational resources on cannabis. The article also encourages arming oneself with facts and research to combat misinformation and to help others understand the benefits and safety of medical cannabis.

Ruby Deevoy, a CBD and cannabis expert, confirms that CBD oil does indeed increase serotonin levels in the body. She explains that CBD interacts with the endocannabinoid system by inhibiting the enzyme that breaks down endocannabinoids, leading to higher levels in the body. Unlike THC and CBG, CBD does not directly activate the endocannabinoid receptors but does activate serotonin receptors, which can affect both mental and physical functions. She compares the potential use of CBD oil to SSRIs, which are commonly prescribed for various mental health conditions, but without the associated side effects. A 2018 study is cited where CBD normalized serotonin activity in stressed rats. Ruby also mentions that CBDA, the raw version of CBD, may be even more effective in activating serotonin receptors. She emphasizes the importance of maintaining healthy serotonin levels for a variety of bodily functions.

The article discusses the decline in smoking rates in the UK from the 1940s to the present, with current figures at 14.7% of the population. It highlights the health risks associated with smoking, such as lung cancer, COPD, and heart disease, and acknowledges the difficulty of quitting due to nicotine addiction. The focus then shifts to CBD (cannabidiol) as a non-addictive, potentially beneficial tool for quitting smoking. The article cites studies from 2013 and 2018 that suggest CBD can reduce cigarette consumption and cravings. It also explores the broader potential of CBD in treating addiction, referencing a peer review of studies on CBD's effects on addictive behaviors. The article explains how CBD interacts with dopamine and serotonin receptors and supports the endocannabinoid system, which may help alleviate withdrawal symptoms and stress-induced relapses. It concludes by suggesting that the various compounds in cannabis, including CBD, can help restore body balance and support quitting smoking when combined with mindful techniques and healthy lifestyle choices.

The article discusses the intertwined history of coffee and cannabis, highlighting their shared journey through historic regulations and biological interactions. It begins with a legend about the discovery of coffee in Ethiopia and traces its widespread use and subsequent bans in various regions, drawing parallels with the use and prohibition of cannabis. The article notes that both substances were used medicinally and socially, and faced similar resistance from ruling powers. It then describes a role reversal in the 19th century where coffee became a mass-produced staple while cannabis was prohibited. The article also touches on the science behind why coffee and cannabis might be a good combination, explaining how coffee affects the endocannabinoid system (ECS) by decreasing endocannabinoid levels, while cannabis increases them. The author suggests that using cannabis or CBD with coffee can balance out the effects on the ECS, potentially providing an ideal mix of alertness without stress or jitters. The article concludes with a hopeful note on the changing perceptions of both substances.

The article discusses common reasons why individuals may not experience the desired effects from CBD oil and offers guidance on how to potentially improve outcomes. It emphasizes the importance of consistency in taking CBD oil, comparing it to the regimen of taking antibiotics. The article suggests that finding the correct dosage is crucial, as there is no universal dose that works for everyone. It also points out that the specific cannabinoid content may vary between products, and finding the right composition is key to achieving therapeutic effects. Additionally, the article highlights the low bioavailability of CBD oil and suggests methods to increase absorption, such as taking it sublingually and considering water-soluble options or CBDa. Lastly, it advises patience, as it may take time for CBD to have an effect on the body's endocannabinoid system.

The article discusses the changing face of cannabis consumption, highlighting the increase in female users, particularly in America where regulations have loosened. It points out that while cannabis remains illegal without a prescription in the UK, there is a significant number of people using it for medicinal and recreational purposes. The article criticizes the UK's outdated perception of cannabis and its users, and the lack of market targeting towards women, who are major contributors to household spending and healthcare decisions. It also mentions the rise of high-quality, women-focused cannabis brands in America and Canada, and calls for a similar evolution in the UK. The article emphasizes the need for the UK cannabis industry to modernize its regulations and recognize the growing female consumer base.

Ruby Deevoy, a CBD and cannabis expert, addresses a reader's concern about their GP's lack of support for medical cannabis in the UK. She explains that while many doctors may still hold stigmatized views on cannabis, organizations like the Medical Cannabis Clinicians Society are working to educate the medical community. Ruby advises the reader that they can seek a private medical cannabis prescription without their GP's approval, by obtaining their medical records and consulting with a private clinic. She also notes that patient-initiated private prescriptions may influence GPs to refer other patients for medical cannabis, suggesting that patient advocacy can help change doctors' perspectives. Ruby encourages the reader to educate their GP on cannabis studies and the MCCS to further this progress.

Ruby Deevoy, the resident CBD and cannabis expert for Leafie, addresses a question about the difference between smoking cannabis and vaporising it. She explains that whole plant cannabis contains a variety of compounds such as cannabinoids, terpenes, and flavonoids, which have therapeutic potential and affect the intensity of the high from THC. Vaporising allows for precise temperature control, which can preserve these compounds, unlike smoking where they are mostly destroyed. Ruby provides a guide to the vaporising temperatures of various compounds, highlighting their benefits and flavors. This information helps users tailor their vaping experience for specific effects, whether medicinal or recreational.

The article reviews various dog beds available in the UK, providing insights into their features, benefits, and drawbacks. The journalist has personally tested these beds with different dogs, including puppies, rescues, elderly, and nervous dogs, to determine the best options. The beds are evaluated based on factors such as comfort, design, value for money, and special features like orthopaedic support, waterproofing, and anti-bacterial properties. The article also includes advice from veterinary nurse and canine behaviourist Rachel Bean on choosing the right bed for a dog's needs. The top picks include beds from Baker & Bray, Three Peaks, Red Dog, Get Laid Beds, Tuffies, Omlet, Earthbound, Lords & Labradors, Cornish Beds, and Wainwright's, with prices ranging from affordable to luxury options.

The article explores the theory that consciousness may reside in the endocannabinoid system (ECS). The author reflects on the nature of consciousness, the lack of material evidence for it, and how it might be intertwined with spirituality and quantum mechanics. The article discusses historical and recent studies, including Tibetan monks' control over their body temperature and metabolism through meditation, and the rise in endocannabinoids during a meditation retreat. The author suggests that the ECS, which is present in all animals and regulates various bodily functions, could be the physical manifestation of consciousness. The piece also touches on the use of cannabis in religious rituals and the potential role of the ECS in acupuncture. The author acknowledges that these ideas are speculative but invites consideration of the ECS as a possible link between our physical and spiritual existence.

The article discusses the significant impact of skin conditions such as acne, psoriasis, and eczema on individuals' lives, emphasizing the physical pain and mental health toll they can take. The author shares personal experiences with acne and describes the life-changing effects of using CBD products, including oral drops and face oil. The article explains the role of the Endocannabinoid System (ECS) in skin health and how CBD can support the ECS to restore healthy skin function. It also highlights the therapeutic potential of CBD oil for treating various skin conditions and the beneficial properties of hemp seed oil for the skin. The author suggests that, in addition to topical application, addressing internal issues with oral CBD products and dietary changes can also be beneficial for skin health.

The article reviews various dog beds available in the UK, providing insights into their features, benefits, and drawbacks. The journalist has personally tested these beds with different dogs, including puppies, rescues, elderly, and nervous dogs, to determine the best options for specific needs. The beds are evaluated based on comfort, design, value for money, and special features like orthopaedic support, waterproofing, and eco-friendliness. The article includes expert opinions from a veterinary nurse and canine behaviourist, Rachel Bean, on what to consider when choosing a dog bed. The journalist also provides a list of the top dog beds for 2023, with detailed reviews of each, including price and where to buy them.

Craig Rands, a 33-year-old veteran, experienced a significant reduction in his PTSD symptoms following a trip to Peru where he underwent hallucinogenic therapy using ayahuasca. The therapy, which induced vivid hallucinations, allowed Rands to confront traumatic memories from his service in Afghanistan. After the effects of the hallucinogen subsided, Rands reported a lasting alleviation of the trauma that had plagued him for 12 years. He was one of the four UK servicemen sent to South America by the charity Heroic Hearts, which specializes in providing psychedelic therapy to veterans.

The article discusses the lagging progress of cannabis legalisation in the UK despite public support. It addresses the stigma and misinformation surrounding cannabis, highlighting the plight of patients who benefit from cannabis but face resistance from the healthcare system and media. The author refutes common anti-cannabis arguments, clarifying that the link between cannabis and schizophrenia is misrepresented and noting that patients use cannabis for its therapeutic benefits, not to get high. The lack of medical training on cannabis in the UK is criticized, and the article points out that 'skunk', a high THC cannabis strain, is used in GW Pharmaceuticals' Sativex, a medical product approved in the UK. The piece aims to educate readers and dispel myths about cannabis.

The article discusses the various methods of cannabis cultivation, focusing on the debate between hydroponics and living soil techniques. Hydroponics is known for its rapid growth and high yield, but critics argue it compromises quality. Living soil, an organic approach where the soil itself is nourished to feed the plants, is gaining popularity for producing higher quality cannabis with better taste, smell, and a healthier profile of terpenes and cannabinoids. Felix Arkin of Dr Organics Living Soil is a proponent of this method. The article also covers the introduction of Living Soil-grown cannabis to the UK medical market through a partnership between 4C labs and The Green Organic Dutchman Ltd., which will supply 600 kg of Living Soil flower annually to the Mamedica clinic. James Smith of 4C labs highlights the potential benefits for patients, including higher levels of minor cannabinoids and terpenes.

Ruby Deevoy, a CBD and cannabis expert, addresses a question about whether smoking weed can prevent Covid-19. She clarifies that while certain cannabinoid acids have shown potential in studies to be developed into medicine against Covid-19, smoking weed does not provide these benefits as the acids transform into different compounds when heated. She explains that cannabinoid acids like CBD-A and CBG-A have health benefits and suggests ways to consume them, such as through certain CBD teas that do not convert the acids into cannabinoids. Ruby recommends Biobloom Organic Hemp Tea and Biopurus 4% full spectrum hemp tea for those looking to include cannabinoid acids in their diet.

A parent shares their experience of 'world schooling' their neurodiverse seven-year-old son, taking him out of traditional school to educate him through global travel. They explore geography in Iceland, art in the Netherlands, and biodiversity in the Azores, using the world as a classroom. The family makes sacrifices to afford this lifestyle, including selling their car and budgeting carefully. The article discusses the benefits and challenges of world schooling, emphasizing the hands-on learning and inspiration it provides, which contrasts with the limitations of conventional classroom education.

Morama Holdings, a South African company, is introducing high-quality, organic, sun-grown medical cannabis from their facility in the Maloti Mountains of Lesotho. Emphasizing organic, regenerative farming techniques, local community engagement, and sustainability, the company is committed to natural cultivation methods and community enrichment. CEO Scott Henson and Head of Cultivation Jos Broersen highlight the company's unique approach to growing cannabis, while COO Lee-Anne Jacobs speaks to the positive impact on local employment and skills development. Morama Holdings is also working towards organic certification and contributes to the Eternal Flame Cook Bag project, showcasing their dedication to environmental and social responsibility.

The article discusses the importance of choosing the right dog bed for a pet's health and comfort. It emphasizes that dogs need an average of 11-14 hours of sleep per day, and the quality of their rest can affect their happiness and receptiveness to training. The author has tested various dog beds on different types of dogs, including puppies, rescues, elderly dogs, and nervous hounds, to determine the best options. Veterinary nurse and canine behaviourist Rachel Bean is quoted, advising on the importance of space in a dog bed and the potential issues with round hard beds. The article also touches on whether dogs prefer beds with sides, noting that it depends on the individual dog's sense of security and comfort. The author promises a list of top five dog beds and reviews to follow in the article.

The article discusses the therapeutic benefits of CBD oil, emphasizing its interaction with the endocannabinoid system and its role in regulating bodily processes. It advises on the importance of choosing high-quality CBD products and the necessity of consistent usage for effective results. The article outlines methods to enhance CBD absorption, such as taking it with fatty foods or after brushing teeth. It also details the testing process, where over 100 products were tested by 10 individuals with various conditions over a year. The best CBD oils for 2024 were selected based on their performance in these tests.

The article discusses the rising popularity of Kambô, a traditional Amazonian ritual involving frog poison, in the UK wellness scene. Celebrities like Georgia Harrison and Ferne McCann have tried it, claiming health benefits. Kambô involves applying secretions from the giant monkey frog to small burns on the skin, which can induce vomiting and other intense reactions. While some users report positive effects, such as clarity and reduced pain, medical experts warn of serious risks, including toxic hepatitis and death. The International Association of Kambô Practitioners (IAKP) offers training for safe practice, but concerns remain about the lack of understanding and potential misuse in the West. Personal accounts from Dr. Emma Cathcart and Jay Woods provide insight into their experiences with Kambô, both positive and cautionary.

The article discusses the rising popularity of the Kambô ritual in the UK wellness scene, where participants undergo a purgative process using the secretion of the Amazonian giant monkey tree frog. Celebrities like Georgia Harrison and Ferne McCann have tried the ritual and reported benefits, but experts warn of serious health risks, including toxic hepatitis and death. The ritual, which involves applying the frog's poison to superficial burns on the skin, is not recognized as medicine in Europe. Despite the risks, the practice is legal in the UK, and the International Association of Kambô Practitioners offers a training program for practitioners. The article includes personal accounts from individuals who have experienced Kambô, detailing both the positive effects and the dangers involved.

The article discusses the rising popularity of the Kambô ritual in the UK wellness scene, a practice involving the application of Amazonian giant monkey tree frog poison to superficial burns on the skin, which induces vomiting, diarrhea, and emotional release. Celebrities like Georgia Harrison and Ferne McCann have tried the ritual and reported benefits such as clarity and energy. However, experts like GP Edna Skopljak warn of serious health risks, including toxic hepatitis and death. The ritual, which has indigenous South American origins, is not recognized as medicine in Europe. Despite the risks, the demand for Kambô ceremonies is growing in the UK, with organizations like the IAKP promoting safe and professional use. Personal accounts from Dr. Emma Cathcart and Jay Woods detail their experiences with Kambô, highlighting both the potential benefits and dangers.

The article discusses the rising popularity of the Kambô ritual in the UK wellness scene, a practice involving the application of Amazonian giant monkey tree frog poison to the skin to induce purging. Celebrities like Georgia Harrison and Ferne McCann have tried it and shared their experiences. The ritual, which has been used by indigenous groups for health benefits, is not recognized as medicine in Europe. Despite claims of health benefits, medical advisor Edna Skopljak warns of serious health risks, including death. The International Association of Kambô Practitioners (IAKP) offers a training program for practitioners, emphasizing the importance of proper guidance. Personal accounts from Dr. Emma Cathcart and Jay Woods, who have experienced Kambô, highlight both the potential benefits and risks associated with the practice.

The article discusses the urgent situation of climate change and the unexpected acceleration towards the point of no return, as reported by the United Nations' Intergovernmental Panel on Climate Change. It highlights that while new technology is not the sole solution, motivation and individual action are crucial. The article explores the unconventional idea that psychedelic drugs, such as ayahuasca and psilocybin, could potentially foster a deeper connection with nature and inspire pro-environmental behavior. Dr. Sam Gandy's research suggests that psychedelics can create lasting nature connectedness, which could be beneficial, especially in countries like the UK with low nature connection. However, the article also presents skepticism and the need for more research. It mentions the 3.5% rule, which suggests that only a small portion of the population needs to be actively involved to create significant change. The article concludes by mentioning a new study at Imperial College London and emphasizes that while psychedelics may remind us of our relationship with Earth, direct action for nature is essential.

The article discusses the use of cannabis and CBD oil for managing symptoms of Multiple Sclerosis (MS). It cites statistics from the MS Society and MyMSteam.com regarding the prevalence of cannabis and CBD use among MS patients. The article notes that many MS patients are prescribed traditional medications like opioids, which have significant side effects. It highlights a study where a majority of patients reported reducing their use of opioids and other drugs after starting cannabis. The NHS's prescription of the cannabinoid-based medication Sativex since 2014 is mentioned, emphasizing the difference between medical cannabis products and over-the-counter CBD oils, particularly in terms of THC content. The article suggests that while THC is known to manage pain and spasticity, CBD may also play a beneficial role, as evidenced by Sativex's formulation.

The article discusses the plight of UK families whose children suffer from severe epilepsy and rely on cannabis-based medication, Celixir20, which has been withdrawn from the market due to the closure of its manufacturer, Breath of Life Pharmaceuticals. The medication was not available through the NHS, forcing families to pay out of pocket. With the shutdown, parents are facing the prospect of either finding a costly alternative at £2,400 a month or reverting to less effective treatments. The Medcan Family Foundation, co-founded by Matt Hughes, is advocating for NHS prescriptions of these medications. The Department of Health and Social Care has responded by emphasizing the need for evidence-based approaches to unlicensed cannabis-based treatments. The article also mentions the #SaveTheUnicorn campaign, which seeks to raise awareness and find solutions for the affected patients.

The article discusses the plight of UK families whose children suffer from severe epilepsy and rely on cannabis-based medication, Celixir20, which is no longer available due to the manufacturer, Breath of Life Pharmaceuticals, shutting down. The medication was not funded by the NHS, and families had to pay out of pocket, but now face even higher costs for alternatives. Emma Appleby and Matt Hughes, parents of affected children, share their struggles and the significant improvements their children experienced on Celixir20. The Medcan Family Foundation, co-founded by Hughes, aims to help families access these medications and push for NHS prescriptions. The Department of Health and Social Care comments on the situation, emphasizing an evidence-based approach to unlicensed treatments. The article also mentions the #SaveTheUnicorn campaign, which seeks to raise awareness and find solutions for the affected patients.

The article discusses the plight of UK families whose children suffer from severe epilepsy and rely on cannabis-based medication, Celixir20, which is no longer available due to the manufacturer, Breath of Life Pharmaceuticals, shutting down. The medication was not funded by the NHS, and families had to pay out of pocket. With the drug's unavailability, parents are facing the prospect of paying £2,400 a month for alternative treatments or watching their children's health deteriorate. The Medcan Family Foundation, co-founded by Matt Hughes, is advocating for NHS prescriptions of these medications. The Department of Health and Social Care insists on an evidence-based approach to unlicensed cannabis-based treatments. The article also mentions the #SaveTheUnicorn campaign, which seeks to raise awareness and prompt MPs to find a solution for the affected patients.

Labour MP Charlotte Nichols shared her personal struggle with PTSD in parliament, advocating for psilocybin as a potential cure. Dr. Jo Neill, a psychopharmacology professor at the University of Manchester, supports the claim that psilocybin can heal, citing its ability to manage symptoms with fewer side effects than traditional drugs. Despite evidence and support from celebrities, psilocybin remains a schedule 1 drug in the UK, indicating no medicinal value. Keith Abraham, CEO of Heroic Hearts, has called for the rescheduling of psilocybin to aid veterans. Studies have shown psilocybin's safety and efficacy in treating mental health conditions, and phase 3 clinical trials are underway. Rebecca Allen Tap, a cancer patient, shared her positive experience with psilocybin in managing her mental health. The article discusses the intersection of clinical and spiritual approaches to mental health treatment and the potential for psilocybin to play a role in this paradigm shift.

Ruby Deevoy recounts her experience at Portugal's first CBD spa, Pine Cliffs Resort's Serenity Spa in Albufeira, where she received a CBD massage. The spa focuses on holistic well-being, offering treatments that align mind, body, and spirit, including nutrition plans and fitness classes. Maria D’Orey, the spa director, emphasizes the importance of full spectrum CBD products for a superior spa experience. The CBD treatments, particularly massages using transdermal balms, are touted for their therapeutic benefits, including anti-inflammatory and antioxidant properties, and their ability to soothe both body and mind. Deevoy reports feeling more relaxed and patient after the massage, and enjoying better sleep.

Hannah Deacon, who successfully campaigned for her son Alfie Dingley to receive medical cannabis on the NHS to treat his severe epilepsy, has been exploited by a CBD oil company, Swiss Peak CBD. The company used her image and a clip from her appearance on 'Loose Women' to promote their product on TikTok, falsely suggesting it could treat epilepsy. Hannah has condemned the misuse of her endorsement, highlighting the danger it poses to vulnerable individuals seeking treatment. She has reported the company to the MHRA and the Advertising Standards Authority. Swiss Peak CBD admitted to a 'horribly bad judgement call' and has since removed the videos from TikTok.

The article discusses the prevalence of skin conditions in the UK and the impact they have on people's confidence. It highlights the potential benefits of CBD skincare products for various skin issues, including acne, eczema, and inflammation. The article details how CBD can normalize sebum production, assist in skin cell turnover, and reduce free-radical damage. Over a year, the article's authors tested hundreds of CBD skincare products on a diverse group of testers with different skin types and conditions. The products were evaluated based on various criteria, including consistency, absorbability, scent, packaging, ingredients, price, and effectiveness. The article concludes by teasing the best CBD skincare products for 2023 without actually listing them.

The article is a personal account of an individual's transformative experience with psychedelics and how it led to a re-evaluation of life. After a crisis of self-worth and a pursuit of success that was detrimental to his health, the author found healing through psychedelic experiences. This change resulted in the end of his marriage but also the beginning of a new relationship with Shannon, with whom he established CAIM, a retreat in Scotland for drug-free trauma release and acceptance. The author, now an ambassador for Heroic Hearts, dedicates himself to helping others with mental trauma, inspired by how psychedelic medicine saved his life.

The article discusses the nuances of cannabis use and misuse, emphasizing that the line between beneficial and problematic use is not clear-cut and varies from person to person. It highlights that while cannabis can offer therapeutic benefits and help in managing addiction to more harmful substances, it can also lead to misuse and addiction. The article cites Dr. Mark Ware's overview of cannabis for pain management and Dr. Ben Sessa's survey on substance use reduction due to cannabis. Dr. Simon Erridge from Sapphire Medical Clinics defines problematic cannabis use and addiction, and the article suggests that psychological approaches like cognitive behavioural therapy are the primary treatment options. It also explores the potential of CBD in treating addiction, referencing various studies. The author, Ruby Deevoy, is a UK-based cannabis journalist with extensive experience in the field.

The article discusses the impact of medical cannabis since its legalization in 2018, highlighting its effectiveness for various conditions. It explains that while GPs in the UK cannot yet prescribe cannabis-based products, private clinics like Sapphire Medical Clinics in Stirling can. Dr. Simon Erridge from Sapphire Medical Clinics outlines the process for obtaining a prescription, which includes self-referral, a triage assessment, and a consultation, possibly followed by tests. Prescriptions are discussed in a multi-disciplinary meeting and sent to a pharmacy for delivery to the patient. The article also addresses potential GP disapproval and the follow-up process for patients. Costs are mentioned, with chronic pain patients paying an average of £135 a month. The article concludes by listing the conditions eligible for medical cannabis treatment and directs readers to Sapphire Medical Clinics' website for more information.

The article discusses the safety and effects of irradiated cannabis, a process used to sterilize medical cannabis products to meet EU-GMP safety standards. It explains that while irradiation is used to kill microbes and extend shelf life, concerns exist about its impact on the therapeutic benefits of cannabis. The article explores different types of radiation used in the process, the necessity of irradiation for immune-compromised patients, and the potential risks and benefits. It also examines the impact of irradiation on the composition of cannabis, including cannabinoids and terpenes. The article suggests that more research is needed to fully understand the effects of irradiation on cannabis and that patients should have access to both irradiated and non-irradiated products, with full disclosure of the product's status. The article has been fact-checked by experts in the field.

Rory Lamont, a former international rugby player, shares his transformative experience with psychedelics, particularly iboga, which he sought out after struggling with the physical and mental toll of his sports career. After retiring due to a severe injury and feeling suicidal, Lamont found healing through psychedelic therapy in Costa Rica. His experience led him to re-evaluate his life, eventually setting up a retreat in Scotland called CAIM, aimed at helping others through drug-free trauma release. Lamont is now an ambassador for Heroic Hearts, an organisation supporting individuals with mental trauma, and advocates for the therapeutic use of psychedelics, which have been gaining recognition in the medical community.

The article discusses the popularity and legal ambiguity of CBD flower in Europe, emphasizing its preference among consumers over other forms of cannabinoids. CBD, known for its wide market presence, overshadows other beneficial cannabinoids and compounds like CBG, CBC, and terpenes. The author explains that while 'whole plant' and 'full spectrum' oils are available, many consumers prefer the unprocessed plant. The legality of CBD flower in the UK is complex, with strict regulations on which parts of the hemp plant can be used. The article also covers the effects of CBD flower when consumed as tea or through smoking/vaporizing, highlighting the benefits of CBDa. The journalist recommends several CBD flower brands and notes the challenges faced by companies in Ireland due to stringent laws. The author, Ruby Deevoy, is a UK cannabis journalist with a background in the CBD industry.

The article discusses the case of Liam Lewis, a medical cannabis patient in Shetland, Scotland, whose legal cannabis oil was confiscated by Police Scotland despite presenting a Medcan ID card and prescriptions from Sapphire Medical Clinics. The incident underscores the lack of understanding and education among police officers regarding the legal use of medical cannabis. The article criticizes the high number of cannabis seizures in Scotland and the country's drug policy, suggesting a need for reform towards decriminalization and harm reduction. It also highlights the inefficiency of stop-and-search practices focused on drug possession, which may detract from addressing more serious crimes and contribute to negative police-community relations. The author, Ruby Deevoy, calls for a national debate on drug policy and police practices in Scotland.

The article explores the possibility of falling asleep while under the influence of psilocybin, commonly known as shrooms. It references a study from Human Brain Mapping that confirms psilocybin induces a 'dreamlike' state in the brain. While most people report being unable to sleep during a psilocybin trip due to an initial rush of adrenaline and cortisol, some anecdotal evidence suggests that a few individuals have managed to sleep, experiencing intense dreams. The article discusses the potential therapeutic benefits of psilocybin, which are believed to occur whether one is awake or asleep, and the importance of the trip experience itself. It also touches on safety considerations and harm reduction techniques for those who might attempt to sleep while tripping on psilocybin, emphasizing the importance of set and setting, and integration practices post-trip.

The article discusses the growing trend of CBD-infused products and the skepticism surrounding their effectiveness. It specifically focuses on CBD patches, a product that some consumers are uncertain about. The article addresses the question of whether CBD patches are just hype or if they actually work. It concludes that when CBD patches are made with high-quality materials and innovative techniques, they can be effective. These patches are designed to deliver CBD through the skin, reaching muscles, joints, and the bloodstream for targeted application. The article suggests that, unlike some CBD products that may not be worth the investment, well-developed CBD patches can be beneficial to users.

The article discusses Diisopropyltryptamine (DiPT), a psychedelic drug known for inducing primarily auditory hallucinations. First synthesized by Alexander Shulgin in 1980, DiPT's effects on the auditory cortex and thalamus of the brain are a mystery to scientists. Zeus Tipado, a psychedelic neuroscience researcher, explains that while other psychedelics affect both audio and visual perceptions, DiPT uniquely causes 'auditory chaos'. There are no clinical trials on DiPT, and its therapeutic potential is speculative, with some suggesting it could be used to treat tinnitus. The drug can cause unpleasant side effects like ear pressure and tinnitus at high doses. The legality of DiPT varies by country, and due to limited research, its long-term health effects are unknown. The article suggests caution for those interested in experimenting with DiPT.

The article discusses the relationship between cannabis use and sleep, highlighting various statistics and beliefs about the effects of cannabis on sleep cycles. It notes that many people use cannabis to aid sleep, but scientific opinions are divided, especially concerning the impact of THC, the main psychoactive component of cannabis. THC is said to support the initial three stages of sleep but may reduce REM sleep, which could explain why chronic users experience fewer dreams. The article also touches on the use of CBN and CBD in relation to sleep, with CBD showing potential benefits without altering sleep architecture. The author, Ruby Deevoy, is a UK-based cannabis journalist with extensive experience in the field, and she provides insights into how different cannabinoids and terpenes may affect sleep.

The article discusses the potential benefits of CBD oil for managing menopause symptoms. Lesley Hirniak, a 54-year-old hairdresser, experienced relief from joint and muscle pain after using CBD oil from Hapi Hemp. Research suggests that CBD may help balance the body during menopause by supporting the endocannabinoid system and managing symptoms like sleep disturbances and mood fluctuations. While Lesley initially used CBD alone, she later combined it with hormone replacement therapy (HRT) to control hot flushes. The article also mentions a study affiliated with Harvard Medical School, which found high cannabis use among menopausal women for symptom management. Dr. Dani Gordon, an expert in CBD and cannabis medicine, supports the use of full-spectrum CBD oil, which contains small amounts of THC, for treating menopausal symptoms. The article advises consulting with a doctor or a CBD consultancy for personalized advice on using CBD oil for menopause.

The article discusses the challenges of menopause and the lack of adequate treatment options. It highlights a study from the Journal of The North American Menopause Society, which found that a significant percentage of menopausal participants use cannabis to alleviate their symptoms. The article also references historical uses of cannabis for gynecological conditions and includes comments from Dr. Dani Gordon, an expert in cannabis medicine, on the benefits of cannabis for menopausal symptoms. The author, Ruby Deevoy, argues for the need to make cannabis more accessible as a treatment for menopause, given the limited alternatives and the potential benefits it offers.

The article discusses the submission of a New Drug Application (NDA) for MDMA-Assisted Therapy (MDMA-AT) to the U.S. Food and Drug Administration (FDA). The FDA has a 60-day period to decide whether to accept the application for review and to determine the type of review it will undergo, either priority or standard. The anticipated timeline for the review process is either six months for a priority review or ten months for a standard review. The submission marks a significant step in the potential approval of MDMA-AT for therapeutic use.

The article discusses US President Joe Biden's recent decision to pardon all prior federal offenses of simple marijuana possession. The author appears to support Biden's stance on cannabis, suggesting that it is a sensible move and implies that the UK should follow suit. The article criticizes the idea of escalating the classification of cannabis or implementing harsh penalties such as passport confiscation for possession. The author uses Biden's statement that classifying cannabis at the same level as heroin is illogical to bolster their argument.

The article discusses US President Joe Biden's decision to pardon all prior federal offenses of simple marijuana possession, contrasting it with the UK's harsher stance on cannabis, where possession can lead to a five-year prison sentence. The author argues that cannabis has proven therapeutic value and safety, citing over 15,000 UK patients prescribed cannabis and the potential to prevent 47,500 deaths annually in the US if medical cannabis were legal. The article criticizes the UK government's reluctance to legalize cannabis, despite evidence of its benefits and the harms of legal substances like alcohol and tobacco. It also touches on the historical racial injustices associated with drug laws, referencing a statement by Nixon's aide John Ehrlichman that highlights the discriminatory motives behind the war on drugs. The author calls for the UK to follow the US in reevaluating cannabis laws and recognizing the plant's medicinal and social value.

The article discusses the role of Psychedelic Integration Coaches in the context of psychedelic therapy, particularly focusing on their importance in helping individuals process and integrate their experiences with psychedelic substances like psilocybin, MDMA, Ketamine, and LSD. The integration process is crucial for ensuring safety and lasting positive changes, especially for those dealing with trauma. The article features an interview with Matty Evans, a volunteer integration coach with Heroic Hearts, who works with combat veterans using ayahuasca to treat PTSD. Matty explains the preparation, support during the trip, and post-trip integration work he does, emphasizing the need for a supportive network and the profound healing he has witnessed. The article highlights the non-medical background of some integration coaches and the unique challenges and responsibilities they face in their role.

David and James discuss the significant efforts made by Mindset to prepare for the initiation of first in-human clinical trials for one or more of their drug candidates in 2023. The conversation highlights the company's progress in drug development and the steps they have taken to reach this critical stage in bringing new therapeutic options to clinical testing.

Karen Julia, a 44-year-old from Glasgow, shared her experience of how medical cannabis has significantly improved her life after suffering from PTSD due to childhood abuse. She reported that after three months of daily use, she feels better, with improved sleep, no side effects, and a sense of calm. Karen had tried other treatments, including antidepressants and eye movement desensitisation and reprocessing, but found them ineffective for her sleep disturbances. Research presented at the International Cannabinoid Research Society Conference and studies in the US support the efficacy of medical cannabis in reducing PTSD symptoms. Dr. James Rucker from Sapphire Clinics commented on the potential of cannabis in treating PTSD. The article also mentions that medical cannabis oil can be legally prescribed in the UK under certain conditions.

The article discusses the potential benefits of medical cannabis for individuals suffering from post-traumatic stress disorder (PTSD), focusing on the story of Karen Julia, who developed delayed onset PTSD and found significant relief from her symptoms through the use of medical cannabis. New research presented by the UK Medical Cannabis Registry at the International Cannabinoid Research Society Conference indicates that PTSD patients have experienced improvements in their condition after using medical cannabis. The article also references studies from the US that support these findings. Dr. James Rucker from Sapphire Clinics explains how cannabis can dampen the overactivity of the amygdala, which is associated with the fight or flight response in PTSD patients.

The article discusses the potential benefits of prescription cannabis for individuals living with post-traumatic stress disorder (PTSD). It highlights a case study of Karen Julia, who developed delayed onset PTSD following a difficult childhood and found significant relief after using medical cannabis. The article suggests that new studies support the use of cannabis in treating PTSD, and it presents the personal account of a patient who claims to have had her life transformed by the treatment.

Journalist Ruby Deevoy reviews various CBD transdermal products for their effectiveness in relieving joint and muscle pain. The article discusses the benefits of CBD for conditions like rheumatoid arthritis, fibromyalgia, MS, and for muscle recovery post-workout. It differentiates between topical and transdermal products, explaining that transdermal products are designed to penetrate deeper into the skin to reach muscles and internal discomfort. The article also addresses the skepticism around CBD's effectiveness and cites studies that support its use for pain relief. Four specific products are recommended: a citrus-derived CBD gel, The Tonic CBD Patches, Grass & Co Ease Balm, and Dermactiva Warming Muscle Cream, the latter of which contains cannabis seed oil but no CBD.

The article discusses the challenges faced by chronic pain and epilepsy sufferers in the UK who are growing their own medical cannabis due to the limited availability of the drug on the NHS. Amy Childs, a reality TV star, is campaigning to make medical cannabis more accessible through the NHS after being moved by the story of six-year-old Jorja Emerson, who has severe epilepsy. Jorja's father, Robin Emerson, claims that medical cannabis oil has significantly reduced her seizures. Despite medical cannabis being legal in the UK, the NHS's demand for more trials on the drug's safety has resulted in few prescriptions, forcing families to pay high costs for private treatment or risk criminal charges by growing their own. The article highlights the plight of individuals like John Browne, who grows his own cannabis to manage chronic pain, and the broader issue of drug policy in the UK.

Amy Childs, a former star of 'The Only Way Is Essex', has launched a campaign to make medical cannabis more accessible through the NHS. Moved by the story of six-year-old Jorja Emerson, who suffers from severe epilepsy, Amy is advocating for the drug to be more widely available. Jorja's father, Robin Emerson, has stated that medical cannabis oil has significantly reduced his daughter's seizures. Despite medical cannabis being legal in the UK, the NHS's demand for more trials on the drug's safety has led to few prescriptions being issued, forcing families to pay for expensive private treatments or to grow their own, risking criminal charges. Amy has started a petition and is seeking a meeting with Prime Minister Boris Johnson to discuss the issue, emphasizing the financial and emotional burden on families needing the medication.

The article discusses the issue of cannabis dependency and the stigma surrounding cannabis use, particularly in the context of medical treatment in the U.K. The author argues that while cannabis dependency is a real concern, it is often exaggerated due to media-fueled moral panic and anti-cannabis propaganda. The article highlights that when cannabis is prescribed by a clinician, the likelihood of addiction and abuse is extremely low. It also points out that cannabis can be effective in treating a range of conditions without causing a 'high'. Experts like Dr. Ben Sessa and Dr. Leon Barron are cited to support the argument that addiction is more about predisposition than the substance itself and that medical cannabis can be used responsibly under clinical guidance. The author, Ruby Deevoy, criticizes the current state of cannabis regulation and education, suggesting that better understanding and responsible use education could reduce the risks associated with cannabis.

Alison McEntee, a 51-year-old learning development professional from Glasgow, has experienced a remission in her multiple sclerosis (MS) symptoms after using medical cannabis. Initially prescribed Plegridy, which had severe side effects without relief, Alison turned to cannabis following a recommendation from a Facebook support group. Despite the initial fear of sourcing it illegally, she found significant symptom relief. In 2019, she obtained a private cannabis prescription but is advocating for NHS accessibility due to the high cost, especially in light of rising living expenses. Alison has reached out to the First Minister to address this issue, as she believes cannabis has been a life-changing treatment for her MS.

Claire Bywalec, a piano teacher and mental health crisis worker, suffered a horse riding accident at 13, leading to chronic pain and a diagnosis of Fibromyalgia. After years of taking prescribed medications, including Gabapentin and co-codamol, Claire turned to cannabis, which she initially used illegally. She found significant relief from her pain and an improvement in her mental health. Eventually, Claire received a private prescription for cannabis oil through Project Twenty21. Her experience with cannabis has been positive, allowing her to manage her pain effectively and improve her quality of life. Claire now advocates for the medicinal use of cannabis and works on a crisis helpline, supporting others with their mental health.

Collette Stevenson MSP has initiated a cross-party members debate in the Scottish Parliament regarding access to medical cannabis, inspired by the case of nine-year-old Cole Thomson, who is seizure-free since 2019 due to medical cannabis. Cole's mother, Lisa Quarrell, struggles to afford the £1,300 monthly cost for Cole's prescription and has been campaigning for NHS access. Despite facing a dire prognosis in infancy, Cole's condition improved dramatically with the use of whole plant cannabis oil, after conventional treatments and surgeries failed. The debate aims to address the challenges faced by families like Cole's in funding treatment and the restrictive prescribing rules. Stevenson supports calls for rule changes to allow GPs to prescribe unlicensed cannabis-based medicinal products and for the government to consider observational trials alongside clinical trials.

The article discusses the impact of whole-plant cannabis oil on children with severe treatment-resistant epilepsy, highlighting the case of Emily Howis's daughter, Clover, who has seen a dramatic reduction in seizure frequency since starting the treatment. Despite the legalization of medical cannabis in the UK in 2018, it remains largely unavailable on the NHS, forcing families like the Howises to spend large sums of money on private prescriptions. The article references a study by Drug Science that showed an 86% reduction in seizure frequency among children using the oil. Experts argue that wider NHS access to cannabis could save money by reducing hospital stays and other medical costs. However, barriers such as lack of doctor training, prescribing frameworks, and randomized control trials persist. The article calls for the NHS to make this treatment more accessible to patients in need.

Alison McEntee, a 51-year-old woman from Glasgow, has found relief from her multiple sclerosis (MS) symptoms through the use of medical cannabis, after conventional medication like Plegridy failed to help and caused unpleasant side effects. Despite the significant improvement in her condition, including remission confirmed by MRI results, Alison faces the dilemma of affording her medication due to its high cost and lack of NHS support. She has been forced to consider returning to funded pharmaceutical drugs, despite their ineffectiveness and her fear of losing the freedom from MS symptoms that cannabis has provided. Alison's situation reflects the broader issue of access to medical cannabis for patients in the UK, highlighting the physical, mental, and financial struggles they endure.

Journalist Ruby Deevoy reviews her experience at the Montcalm East hotel in London, highlighting its luxurious amenities and the OTO CBD massage at the Bokeh Spa. She describes the hotel's contemporary style, safety features, and in-room technologies, including a variety of control buttons for guest convenience. Deevoy was upgraded to a 'sky high' room with impressive city views and enjoyed the artsy ambiance of the hotel. She details her experience with the 'Amplified' full-body massage, which was more intense than soothing, and mentions the use of CBD-infused body oil during the session. Although she missed out on using the pool and other relaxation facilities, she notes the hotel's focus on art and its appeal to the creative crowd in Shoreditch.

The article discusses the challenges faced by patients in the UK in accessing whole plant cannabis for medical purposes, despite its legalization for prescription in 2018. The author criticizes the NHS for its bureaucratic hurdles and the influence of pharmaceutical companies, which result in only a handful of patients receiving the drug through the NHS. The article highlights the case of GW Pharmaceuticals' Epidyolex, which has seen significant revenue despite being less effective and having more severe side effects than whole plant cannabis. The author argues that the government and regulatory bodies, such as the MHRA and BPNA, use the need for more evidence as a pretext to restrict access to cannabis, despite ample Real World Data supporting its safety and efficacy. The article suggests that financial interests are at play, as wider access to cannabis could significantly reduce pharmaceutical profits.

The article discusses the challenges faced by patients in accessing medical cannabis despite its proven safety and therapeutic effectiveness. It highlights the historical use of cannabis in medicine and its current legal status in various US states and recognition by the UN. The UK, being the world's largest producer of medical cannabis, still has restrictive NHS policies, making access to cannabis medication expensive and limited. Personal stories, like that of Lucy Stafford, illustrate the positive impact of cannabis on health. The article criticizes the lack of education among medical professionals about cannabis and the endocannabinoid system. It suggests that pharmaceutical companies may be obstructing access to protect their profits. The article calls for a change in medical training and policy to improve access to medical cannabis.

Ruby Deevoy, a seasoned journalist in the cannabis industry, shares her top five CBD oils after extensive testing. She emphasizes the importance of choosing high-quality CBD oil, which can be life-changing for its users. Deevoy explains the benefits of CBD oil, how it supports the endocannabinoid system, and what to look for in a good product, including organic sourcing and the presence of a range of cannabinoids and terpenes. She reviews five CBD oils: Amma Life 10% Boost, Dreem Distillery, Herts Hemp CBG oil, Ardoa Amber M-Drops, and Mindful Extracts, highlighting their unique benefits and uses. Deevoy also advises on the proper way to take CBD oil and the importance of consistency and patience for best results.

Philip Antony Bevington, an 81-year-old with terminal kidney failure, turned to growing cannabis for medicinal purposes after pharmaceutical drugs worsened his condition. Despite the illegality of his actions, he found significant health benefits from using cannabis, including improved kidney function and overall well-being. After being charged with cultivation, he became a legal cannabis patient through Drug Science's Project Twenty21 but still faced legal challenges. Tony criticizes the UK's drug enforcement policies and is involved with WTU to advocate for the deregulation of cannabis. His story highlights the ongoing debate and stigma surrounding medical cannabis in the UK.

The article discusses the safety and accessibility of medicinal cannabis in the UK, focusing on the case of an 8-year-old boy, Murray Gray, who requires a cannabis oil called Bedrolite to control his seizures. Despite its efficacy and safety, Bedrolite is not readily available on the NHS, leading to high costs for the family. The author criticizes the inconsistency in NHS prescriptions for cannabis-based medications and suggests that the real barrier to prescribing cannabis oils is not a lack of evidence but a lack of education among doctors about the endocannabinoid system and cannabis. The article also highlights the potential of real-world evidence in informing safety decisions, as seen during the COVID-19 pandemic, and calls on Nicola Sturgeon to reconsider the stance on medicinal cannabis in light of the overwhelming evidence of its safety and therapeutic potential.

The article discusses the lack of research, treatment options, and proper diagnosis for Endometriosis, a condition affecting a significant portion of the global female population. It highlights the long duration and numerous doctor visits required for diagnosis, and the minimal research funding for reproductive health, especially when compared to male conditions. The article also mentions the All-Party Parliamentary Group on Women’s Health report on late diagnosis and treatment for gynaecological conditions. Dr Shree Datta from INTIMINA offers insights into managing Endometriosis. The piece further explores the potential of cannabis, particularly CBD and THC, in treating Endometriosis, supported by research and the theories of Dr Ethan Russo on ECS dysfunction. It suggests that while more research is needed, cannabis holds promise for symptom management and treatment of Endometriosis.

The article discusses the impact of the National Institute for Healthcare and Excellence (NICE) guidelines that discourage long-term opioid prescriptions for chronic pain, affecting millions in the UK. It explores the potential of medical cannabis as a safer alternative, highlighting its legal availability since 2018 and the growing body of research supporting its efficacy. Personal stories from patients Gillian Flood and Lucy Stafford illustrate the life-changing benefits of medical cannabis for conditions like fibromyalgia and Ehlers-Danlos syndrome. Despite positive outcomes, the article notes the stigma and lack of widespread NHS support for medical cannabis, with most doctors untrained in its use. Dr. Simon Erridge from Imperial College London comments on the limited medication options for chronic pain and the promise of medical cannabis in addressing the opioid epidemic.

The article discusses the impact of a significant price increase for medical cannabis products on patients enrolled in Project Twenty21 (T21), a subsidized medical cannabis program in the UK. The price hike, which in some cases is more than 130%, is forcing patients to choose between essential needs and medication, with some resorting to illegal markets or considering criminal activities to afford their prescriptions. The article highlights personal stories of patients affected by the price increase and examines the broader implications for drug policy and healthcare in Scotland. It also mentions the London Mayor's pilot diversion scheme for cannabis possession and calls for similar measures in Scotland, as well as a push for decriminalization and better access to medical cannabis through the NHS.